Product Monograph - Neostigmine Methylsulfate Injection, USP (Jamp Pharma)
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Symptoms: Muscarinic and nicotinic effects (see ADVERSE REACTIONS). Distinguish from myasthenic crisis with edrophonium chloride, if necessary.
Treatment: Control muscarinic effects with IV atropine, followed by intramuscular (IM) atropine every 2 to 4 hours. Assist ventilation and treat convulsions or shock if necessary.
| For management of a suspected drug overdose, contact your regional poison control centre. |
|---|
DOSAGE AND ADMINISTRATION
Intestinal atony, postoperative: Prophylaxis: 250 mcg subcutaneous (SC) or IM before or immediately after operation, repeated every 4 to 6 hours SC. Treatment: 500 mcg SC, IM (or possibly IV) repeated at intervals of 4 to 5 hours.
Urinary Retention: Prophylaxis: 250 mcg as for intestinal atony. Treatment: 500 mcg SC or IM and apply heat to the lower abdomen. If urination does not occur within one hour, the patient should be catheterized. After the patient has voided, continue the 500 mcg injections at 3-hour intervals for at least 5 additional injections.
Curare Antagonist (to neutralize the effect of curare in surgical anesthesia and shock therapy): 0.5 to 2 mg IV. Atropine sulfate 0.6 to 1.2 mg IV should also be given.
DOSAGE FORMS, COMPOSITION, AND PACKAGING
Neostigmine Methylsulfate Injection, USP is a clear, colourless solution. Each mL contains neostigmine methylsulfate 0.5 mg and the following non-medicinal ingredients: acetic acid for pH adjustment, phenol 4.5 mg as preservative, sodium acetate trihydrate 0.2 mg as a buffer and sodium hydroxide for pH adjustment and water for injection. Available in 10 mL clear glass vials (Multidose), 10 vials per carton.
STORAGE AND STABILITY
Store between 15- 30°C. Protect from light. Multi-dose. Discard 28 days after initial use.
Do not use product if mixture (solution) shows haziness, particulate matter, discolouration, or leakage.
REFERENCES
- 1)
NEOSTIGMINE OMEGA (Neostigmine Methylsulfate Injection USP), Prescribing
Information, Omega Laboratories Limited, Date of revision: November May 24, 2012.
If you want more information about Neostigmine Methylsulfate Injection, USP:
- Talk to your healthcare professional
- Find the full Product Monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer’s website (www.jamppharma.com), or by calling at 1-866-399-9091.
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Last Approved: April 26, 2023